News & Updates
Filter by Specialty:
Expectant mums’ use of dolutegravir safe for babies
Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.
Expectant mums’ use of dolutegravir safe for babies
04 Aug 2022Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022Do cardiovascular drugs worsen COVID-19 outcomes?
Cardiovascular medications, such as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, do not induce poor clinical outcomes in patients with COVID-19 and thus should not be discontinued, suggest the results of a meta-analysis.
Do cardiovascular drugs worsen COVID-19 outcomes?
03 Aug 2022GLP-1 RAs help lower serum uric acid concentration
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class mainly used for the management of type 2 diabetes, significantly reduces serum uric acid (SUA) concentration, a recent study has shown.
GLP-1 RAs help lower serum uric acid concentration
03 Aug 2022VTE prevention in pregnancy: Does heparin dose matter?
In pregnant women with a history of venous thromboembolism (VTE), receipt of low-molecular-weight heparin (LMWH) at either a weight-adjusted intermediate-dose or fixed low-dose during the antepartum and postpartum periods results in similar VTE incidence, according to findings of the Highlow study. However, there was a numerically lower incidence of VTE during the postpartum period with intermediate-dose LMWH.
VTE prevention in pregnancy: Does heparin dose matter?
02 Aug 2022SGLT2 inhibitors show renal benefits vs GLP-1 RAs in T2D patients in the real world
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.